Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077375 · ClinicalTrials.gov registry record · Phase 4
Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 107
- Enrollment target
NCT01077375 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 107 participants.
The verdict
NCT01077375, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 107 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.
Interventions
- DRUG Placebo
- DRUG Milnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077375
The ClinicalTrials.gov registry entry for NCT01077375 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01077375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077375 about?
NCT01077375 is a clinical study titled "Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia". The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.
What is the current status of trial NCT01077375?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 107 participants. The study started on 2010-02. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01077375?
The interventions under investigation include: Placebo (DRUG), Milnacipran (DRUG).
Who is sponsoring clinical trial NCT01077375?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.